Pfizer announced today that it had chosen to terminate further development of danuglipron (also known as PF-06882961), which was a GLP-1 receptor agonist that was being developed for the treatment of patients with obesity. It is not because there...
Annexon had some really positive news to give an update on for investors last week at the AAN Annual Meeting, which took place between April 5th - 9th of 2025 in San Diego California. It gave an oral presentation...
It seems that Bristol-Myers Squibb is set to put its hat into the first-line liver cancer treatment space. The reason why is because just the other day it nabbed FDA approval of its drugs OPDIVO (nivolumab) and YERVOY (ipilimumab)...
It seems that Opthea was placed in a tough spot after it had failed both of its phase 3 studies known last month. Both of these phase 3 studies were known as COAST and ShORe used the drug sozinibercept...
Tempest Therapeutics announced today that it would explore strategic alternatives in order to maximize stockholder value. The thing is that the company achieved great success when it surged 4,000% in one day on the back of news that it...
Bristol-Myers Squibb scored a huge win the other day because it was able to receive FDA approval of OPDIVO and YERVOY for 1st-line and 2nd-line treatment of adult and pediatric patients ages 12 and older with unresectable or metastatic...
